Vivos Therapeutics Requests Approval for Reverse Stock Split and Common Stock Issuance

Filing content

The company submitted proposals for a 1-for-20 to 1-for-40 reverse stock split to maintain Nasdaq listing and for the issuance of common stock upon conversion of securities held by New Seneca Partners.